Filing Flows › ENvue Medical (FEED) › Q1 2026
ENvue Medical (FEED) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 18, 2026
ENvue Medical (FEED) reported revenue of $653K for the first quarter 2026 (Q1 2026), -36% from a year earlier and +109% from the quarter before. Operating margin was -568.3%, net loss $3.8M (585.3% of revenue).
ENvue Medical, Q1 2026: revenue $653K (-36% year over year), operating margin -568.3%, net loss $3.8M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $653K | +109% | -36% |
| Operating profit | −$3.7M | — | — |
| Net earnings | −$3.8M | — | — |
| Operating cash flow | −$4.3M | — | — |
What changed
Revenue was $653K in Q1 2026, down 36% year over year and up 109% from the previous quarter. Nano Vibronix was the largest line at 82% of revenue. Nano Vibronix lost $388K year over year (down 42%), 104% of the total change.
Operating costs exceeded revenue by $3.7M, an operating margin of -568.3%. The fastest-growing cost line was Sales & marketing (+121%). The quarter ended with a net loss of $3.8M, narrower than the previous quarter's $12.9M loss.
Operating cash flow was −$4.3M. Non-cash charges added back $217K of depreciation and amortization. Working capital and other items used $707K. Capital expenditures of $17K exceeded it, leaving free cash flow of −$4.3M.
Questions
What was ENvue Medical's revenue in the first quarter 2026?
ENvue Medical (FEED) reported revenue of $653K for the first quarter 2026 (Q1 2026), -36% from a year earlier and +109% from the quarter before.
Was ENvue Medical profitable in the first quarter 2026?
Operating loss was $3.7M (-568.3% of revenue) and net loss $3.8M.
Source: ENvue Medical 10-Q on SEC EDGAR.